Abstract
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous subtype of non-Hodgkin lymphoma in which better or poorer outcomes are associated with specific tumor-cell and tumor-microenvironment characteristics. However, identifying such biomarkers has required the use of molecular techniques that are not readily available in routine clinical practice. Now, investigators have developed a biologic prognostic model (BPM) that uses widely available immunohistochemistry methods …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
